美股新聞 標題聯播 · 近 24 小時 284 則 · 25 個來源 · 最新 9/20 06:32
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · KOD近 30 天 1 則 · 第 1 / 1 頁
- Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts
- Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
- Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
- KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
- Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
- Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
- Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans
- Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
- A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda
- Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。